Literature DB >> 18986324

Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.

Haroldo A Toque1, Fernanda B M Priviero, Saiprasad M Zemse, Edson Antunes, Cleber E Teixeira, R Clinton Webb.   

Abstract

1. The anococcygeus muscle is part of the erectile machinery in male rodents. Phosphodiesterase (PDE) 5 inhibitors enhance and prolong the effects of cGMP, which has a key role in penile erection. The aim of the present study was to provide a functional and biochemical comparison of the three PDE5 inhibitors, namely sildenafil, tadalafil and vardenafil, in the rat anococcygeus muscle. 2. Muscle strips were mounted in 4 mL organ baths and isometric force recorded. Levels of cGMP were measured using an enzyme immunoassay kit. Western blots were used to determine PDE5 protein expression. 3. The PDE5 inhibitors concentration-dependently relaxed carbachol-precontracted anococcygeus muscle; however, vardenafil was more potent (pEC(50) = 8.11 +/- 0.05) than sildenafil (7.72 +/- 0.06) or tadalafil (7.69 +/- 0.05). Addition of N(G)-nitro-l-arginine methyl ester (100 micromol/L) or 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (10 micromol/L) to the organ baths caused significant rightward shifts in concentration-response curves for all PDE5 inhibitors. 4. Sildenafil, tadalafil and vardenafil (all at 0.1 micromol/L) caused leftward shifts in the glyceryl trinitrate (GTN) concentration-response curves (by 4.0-, 3.7- and 5.5-fold, respectively). In addition, all three PDE5 inhibitors significantly potentiated relaxation responses to both GTN (0.01-10 micromol/L) and electrical field stimulation (EFS; 1-32 Hz), with vardenafil having more pronounced effects. 5. All three PDE5 inhibitors reduced EFS-evoked contractions in a concentration-dependent manner over the concentration range 0.001-1 micromol/L. There were no significant differences between the effects of the three PDE5 inhibitors. 6. Vardenafil (0.01-0.1 micromol/L) was more potent in preventing cGMP degradation in vitro than sildenafil (0.01-0.1 micromol/L) and tadalafil (0.01-0.1 micromol/L). 7. Under control conditions, the expression of PDE5 was higher in the anococcygeus muscle than in the corpus cavernosum. 8. In conclusion, PDE5 inhibitors enhance exogenous and endogenous nitric oxide-mediated relaxation in the rat anococcygeus muscle. The potency of vardenafil was greater than that of either sildenafil or tadalafil.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18986324      PMCID: PMC3022481          DOI: 10.1111/j.1440-1681.2008.05071.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  48 in total

Review 1.  The pharmacology of nitric oxide in the peripheral nervous system of blood vessels.

Authors:  Noboru Toda; Tomio Okamura
Journal:  Pharmacol Rev       Date:  2003-06       Impact factor: 25.468

Review 2.  Pharmacology of phosphodiesterase 5 inhibitors.

Authors:  Serge Carrier
Journal:  Can J Urol       Date:  2003-02       Impact factor: 1.344

3.  Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery.

Authors:  Ichiro Sakuma; Yasuhiro Akaishi; Hiroshi Tomioka; Atsushi Sato; Akira Kitabatake; Yuichi Hattori
Journal:  Eur J Pharmacol       Date:  2002-02-22       Impact factor: 4.432

Review 4.  Cyclic GMP phosphodiesterases and regulation of smooth muscle function.

Authors:  Sergei D Rybalkin; Chen Yan; Karin E Bornfeldt; Joseph A Beavo
Journal:  Circ Res       Date:  2003-08-22       Impact factor: 17.367

Review 5.  Overview of phosphodiesterase 5 inhibition in erectile dysfunction.

Authors:  Raymond C Rosen; John B Kostis
Journal:  Am J Cardiol       Date:  2003-11-06       Impact factor: 2.778

Review 6.  Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system.

Authors:  Donald H Maurice; Daniel Palmer; Douglas G Tilley; Heather A Dunkerley; Stuart J Netherton; Daniel R Raymond; Hisham S Elbatarny; Sandra L Jimmo
Journal:  Mol Pharmacol       Date:  2003-09       Impact factor: 4.436

7.  Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.

Authors:  Mitsi A Blount; Alfreda Beasley; Roya Zoraghi; Konjeti R Sekhar; Emmanuel P Bessay; Sharron H Francis; Jackie D Corbin
Journal:  Mol Pharmacol       Date:  2004-07       Impact factor: 4.436

8.  Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.

Authors:  Byung-Je Sung; Kwang Yeon Hwang; Young Ho Jeon; J I Lee; Yong-Seok Heo; Jin Hwan Kim; Jinho Moon; Jung Min Yoon; Young-Lan Hyun; Eunmi Kim; Sung Jin Eum; Sam-Yong Park; Jie-Oh Lee; Tae Gyu Lee; Seonggu Ro; Joong Myung Cho
Journal:  Nature       Date:  2003-09-04       Impact factor: 49.962

9.  The rat anococcygeus muscle and its response to nerve stimulation and to some drugs.

Authors:  J S Gillespie
Journal:  Br J Pharmacol       Date:  1972-07       Impact factor: 8.739

10.  Pro-erectile effect of vardenafil: in vitro experiments in rabbits and in vivo comparison with sildenafil in rats.

Authors:  F Giuliano; J Bernabe; L Alexandre; U Niewoehner; H Haning; E Bischoff
Journal:  Eur Urol       Date:  2003-12       Impact factor: 20.096

View more
  1 in total

1.  Frequency-dependent characteristics of nerve-mediated ATP and acetylcholine release from detrusor smooth muscle.

Authors:  Basu Chakrabarty; Katie Aitchison; Paul White; Carly J McCarthy; Anthony J Kanai; Christopher H Fry
Journal:  Exp Physiol       Date:  2022-03-04       Impact factor: 2.858

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.